Business Standard

Indoco Remedies rallies 9% after launching Covid treatment drug

Fevindo-400 will be made available at all government approved COVID care centres and selected medical practitioners across the country

covid, coronavirus, vaccine, drug, pharma
Premium

SI Reporter Mumbai
Shares of Indoco Remedies surged 9 per cent to Rs 284 on the BSE on Monday after the pharmaceutical company announced the launch of Fevindo (Favipiravir) 400 mg tablets in India.

Fevindo-400 (Favipiravir) is an antiviral drug, effective against the RNA‐based influenza virus. The drug has been approved by DCGI in the treatment of Covid-19. The drug reduces pill burden by 50 per cent and ensures convenient dosing and better patient compliance, Indoco Remedies said in press release on Saturday.

Fevindo-400 will be made available at all government approved Covid-19 care centres and selected medical practitioners across the

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Sep 28 2020 | 9:24 AM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com